



Mechanical Thrombectomy in Treatment Of Acute Ischemic Stroke

Ahmed Mohammed Ahmed Ali¹, Gharib Fawi Mohammed¹, Mohammed Abdelmoneim Sayed¹, Ahmed Ali Elbassiouny².

1..Department of Neurology, Faculty of Medicine, Sohag University,

2. Department of Neurology, Ain Shams University

Abstract

In the Western world, stroke is the second most normal reason for dementia, the most successive reason for super durable impedance, and the fourth most regular reason for mortality. Endovascular treatment for intense stroke has as of late gone through an upheaval based on effective multicenter randomized clinical preliminaries. For patients with critical vascular impediments, routine mechanical thrombectomy along with intravenous thrombolysis has been shown to have phenomenal outcomes. This strategy diminishes disability, and the benefits are seen in patients of any age and stroke seriousness levels. Season of show, patient clinical status, imaging attributes, and lab tests are huge variables that impact treatment choices.

Key words Large vessels occlusion, a direct aspiration thrombectomy, stent retriever thrombectomy, and acute ischemic stroke.

DOI: [10.21608/smj.2023.192450.1369](https://doi.org/10.21608/smj.2023.192450.1369)

Introduction

One of the leading causes of human disability and death is stroke. Around 80% of all strokes are acute ischemic strokes (AIS).⁽¹⁾ Recanalizing the blocked blood artery as soon as possible and saving the ischemic penumbra are essential components of AIS treatment. Because of its many benefits, including quick recanalization, a low rate of hemorrhagic transformation, and a prolonged window for stroke interventional therapy, endovascular treatment (EVT) in patients with large vessel occlusion (LVO) has received a lot of attention.⁽²⁻⁵⁾ Much work has gone into creating novel recanalization devices with a speedy and high recanalization rate in order to improve the prognosis of stroke victims. Endovascular thrombe-

ctomy (EVT) must be performed within 4.5 hours of the stroke's beginning, albeit it can be performed across a larger time period than intravenous thrombolysis (IVT). Stent-like thrombectomy devices, also known as stent retrievers, were used in 2008 to achieve a breakthrough in the interventional treatment of acute stroke.^(6,7)

Epidemiology

The subsequent driving reason for death overall is stroke.⁽⁸⁾ Every year, 6.5 million individuals pass on from strokes and more than 10 million new strokes happen.⁽⁹⁾ Roughly 33% of stroke survivors are practically reliant at one year after their stroke, making stroke the third greatest reason for early mortality and inability.⁽¹⁰⁾ Auxiliary clinical issues we-

lcomed on by stroke incorporate dementia, despondency, epilepsy, falls, and fractures. The weight of stroke is becoming worldwide because of an expansion in ischemic and hemorrhagic stroke cases as well as passings from stroke⁽¹¹⁾ The quantity of long stretches of life lost to stroke in low-and center pay nations is multiple times higher than in top level salary nations, as per the World Wellbeing Association (WHO), and low-and center pay nations presently repress-ent 85% of stroke passings.⁽¹²⁾ Disturbing stroke rates and a high occurrence of stroke risk variables should be visible in Egypt. The circumstance is more terrible in light of the fact that there are not very many public measurements on strokes.⁽¹³⁾ 951/per 100,000 individuals universally had an ischemic stroke.⁽¹⁴⁾ Ischemic stroke predominance fluctuates in Egypt, from 895/100,000 to.⁽¹⁵⁾ Stroke comes third in Egypt behind coronary illness and gastrointestinal (especially liver) messes, and is firmly trailed by disease (6%) at 6.4% of all fatalities.⁽¹³⁾

Pathophysiology of acute ischemic stroke

Thrombosis, embolism, and focal hypoperfusion are the main causes of ischemic cerebrovascular illness, which can all result in a decrease or stoppage in cerebral blood flow (CBF), which affects neurological function. 20% of cardiac output is directed toward the brain while at rest. It is prone to ischemia, and even minor episodes of ischemia in neurons can trigger a complex cascade of events that results in permanent cerebral damage⁽¹⁶⁾. An adult's CBF typically falls between 50 and 55 ml/100 g/min.⁽¹⁷⁾ Reduced oxygen and glucose delivery as a result of CBF decline during brain ischemia sets off the pathophysiology of stroke. The pathophysiology of an ische-

mic stroke can be divided into two stages:

1. The electroencephalogram turns isoelectric and the evoked responses change when CBF is decreased to roughly 142 ml/100 g/min. Although there remains architecturally intact tissue (ischemic penumbra) and functional impairment in this area, brain damage is recoverable.

2. When CBF drops to approximately 6 ml/100 g/min, brain injury becomes irreversible and presents as an ischemic core infarction. The ischemic penumbra's survival is the clinical aim of acute stroke treatment. Failure of the blood-brain barrier (BBB), excitotoxicity, oxidative stress, inflammation, necrosis, and apoptosis are some of the symptoms, and other complex processes are all part of the pathophysiology of stroke.⁽¹⁸⁾

Mechanical thrombectomy, History of intervention for acute ischemic stroke

The PROACT II (Prolyse in Intense Cerebral Thromboembolism II) preliminary study from 1999 demonstrated the effectiveness of intravascular urokinase support for MCA obstruction.⁽¹⁹⁾

In the end, MT was made possible by these early endovascular techniques.

The MERCI Retriever served as the primary coagulation recovery device (UCLA, USA).

It was applied to the 2005 MERCI study (Mechanical Embolus Expulsion in Cerebral Ischemia).

When paired with rtPA, it showed a recanalization rate of 60.8% as opposed to 46% when used alone.⁽²⁰⁾

7.8% of people experienced the cerebral drain, though. The Multi MERCI trial utilised a MERCI device of a more recent version, which excluded a control treatment group but demonstrated a recanalization rate of 69.5% and favourable clinical outcomes in 34%.⁽²¹⁾

Three unsuccessful randomised clinical trials (RCTs) that were published in 2013 (Blend (Nearby Versus Foundational Thrombolysis for Intense Ischemic Stroke), IMS-3 (Interventional The executives of Stroke 3), and MR Salvage (Mechanical Recovery and Recanalization of Stroke Clusters Using Embolectomy)) reduced MT. These trials failed to demonstrate the further developed efficacy of intra-blood vessel treatments in comparison to.⁽²²⁻²⁴⁾ These early preliminaries' constraints were as per the following: patient determination (demonstrated huge vessel impediment was not a prerequisite for consideration), utilization of more established innovation (primarily original cluster recovery gadgets) and a long deferral from stroke beginning to mediation. Be that as it may, In fact, a post hoc subgroup analysis of patients with demonstrable large artery obstruction who had endovascular cluster recovery within an hour and a half of receiving rtPA shown improvement⁽²⁵⁾

Current evidence for mechanical thrombectomy

Five positive RCTs were distributed in 2015, including Break (Endovascular treatment for Little Center and Front Dissemination Proximal Impediment with Accentuation on Limiting CT to Recanalization Times), Expand IA (Broadening The ideal opportunity for Thrombolysis in Crisis Neurological Shortages - Intra-Blood vessel), and Quick PRIME (SolitaireTM with the Expectation for Thrombectomy as Essential End.⁽²⁶⁻³⁰⁾

These five preliminary studies were subjected to a meta-analysis by the Endovascular Thrombectomy after Massive Vein Ischemic Stroke (HRMES) team, which confirmed the significant benefit of MT in patients with severe Massive

Vein Thromboembolic Stroke.⁽³¹⁾ As indicated by the creators, if endovascular MT was done inside 7.3 hours of the start of side effects, it essentially diminished hindrance at 90 days (mRS 0-2) contrasted with common treatment (46% for the interventional arm and 26.5% for the control populace). A sub-bunch concentrate on uncovered reliable benefits in people over the age of 80, and the quantity of members that should have been treated for MT to diminish impedance by something like one point on the mRS for one understanding was^{2,6.}

Patient eligibility for thrombectomy after acute stroke

Time of presentation

The clinical result is significantly influenced by the window of time between IV rtPA and endovascular thrombectomy (EVT). When administered within six hours of the onset of stroke symptoms, MT had positive clinical effects.⁽³¹⁾ Recent RCTs, DEFUSE 3 (A multicenter randomised controlled trial of endovascular therapy after imaging evaluation for ischemic stroke) and DAWN (Diffusion-Weighted Imaging or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo), demonstrated an overall improvement in function outcome at 90 days in patients treated with MT within 6 to 24 hours or 6 to 16 hours from the onset, respectively.⁽¹⁵⁾

The DAWN and DEFUSE studies suggest that the treatment conundrum of "time is brain" may have shifted to "collaterals are brain." Some patients with collaterals may withstand it for a longer amount of time than others, even if time is still a determinant in the outcome.⁽³²⁾

Age of the patients

High age (> 80 years) should not be viewed as a contraindication for MT, but it is an independent factor that predicts the clinical result.⁽³³⁾ Patients over 80 showed a consistent effect from MT in all age categories, according to the HERMES meta-analysis.⁽³¹⁾

Which arterial occlusions are suitable for thrombectomy?

Five positive RCTs incorporated the ICA and MCA "M1 area". While basically no foremost or back cerebral supply route impediments or "M2" impediments (post bifurcation in the Sylvian crevice) were dealt with.⁽³¹⁾ All preliminaries with basilar supply route blockage were excluded. Recanalization and improved results were seen to be unequivocally associated in one little randomized try, like the front flow.⁽³⁴⁾ As of late Fundamentals (BASilar conduit Global Participation Study) preliminary appearance among patients with stroke from basilar-corridor impediment, endovascular treatment and clinical treatment didn't vary essentially concerning an ideal utilitarian result.⁽³⁵⁾

Couple impediments are impediments or stenosis of cervical ICA with joined impediment of either ICA end, MCA or ACA. The primary objective of treating intense pair impediments is to address the cervical ICA sore with swell angioplasty either no matter what stenting previously or after intracranial thrombectomy. The thrombectomy first methodology enjoys the benefit of quicker recanalization, while fixing the cervical carotid first can enhance securities and anterograde stream not long before the genuine thrombectomy.⁽³⁶⁾

One of the central concerns is utilizing antiplatelet when the stent is set, and the intravenous thrombolytic are frequently mixed. From the restricted information

accessible, stent position during endovascular treatment of patients with pair impediment seems to have lower-than-anticipated paces of unfavorable occasions.⁽³²⁾

Antiplatelet specialist decision might fluctuate, however most focuses use Abciximab (ReoPro) 0.25 mg/kg IV bolus over no less than 1 moment, trailed by 0.125 mcg/kg/min IV ceaseless implantation for 12 hours; not to surpass mixture pace of 10 mcg/min. Two hours before the finish of the mixture, oral Ibuprofen 325 mg and Clopidogrel 75 mg are given, either gulped or through a nasogastric tube on the off chance that the patient doesn't finish the bedside swallow assessment.⁽³²⁾

Another choice was an intravenous bolus of tirofiban (10 mg/kg) directed over a time of 3 minutes; following the intravenous bolus, an intravenous implantation of tirofiban (0.1 mg/kg/min) was kept up with for as long as 24 hours. A stacking portion of 300 mg of clopidogrel was controlled 6 hours before the finish of the tirofiban imbuelement.⁽³⁷⁾

clinical presentation

Patients who show extreme weaknesses with NIHSS somewhere in the range of 8 and 20 are better possibility for treatment since they are bound to profit from reperfusion with EVT. A large portion of the members in the latest RCTs had side effects of moderate-to-serious stroke.⁽³¹⁾

The signs for EVT in patients with low NIHSS are disputable. The vast majority of the preliminaries prohibited patients with NIHSS <10. Nonetheless, late examinations have shown that the normal history of enormous vessel impediment (LVO) strokes related with low NIHSS may not be harmless. Almost a fourth of patients basically oversaw medicinally didn't accomplish freedom at 90 days.⁽³²⁾

Imaging

We should do a thorough examination using multimodal CT or MRI techniques on individuals who are candidates for EVT and who have a clinical picture suggestive for major artery blockage. The availability of CT and the speed with which a stroke imaging regimen using non-contrast CT and CTA can be completed are two of CT's key advantages over MRI.⁽³⁸⁾ The ischemia penumbra can be located and measured using diffusion-weighted imaging MRI or perfusion imaging with perfusion CT. As a result, it is useful in determining if a patient is eligible for EVT during the expanded time window⁽³⁹⁾.

Collateral grade

After MT, patients with moderate to good collaterals experience positive results. Benefits are unclear in people with weak or nonexistent collaterals⁽⁴⁰⁾.

As a result of previous data, American heart association (AHA) guideline provides level 1A evidence for MT for a patient with:

- (1) Pre-stroke mRS score of 0 to 1.
- (2) Causative impediment of the interior carotid course or MCA section 1 (M1).
- (3) Age ≥ 18 years.
- (4) NIHSS score of ≥ 6 .
- (5) Parts of ≥ 6 .
- (6) Treatment can be started (crotch cut) in the span of 6 hours of side effect beginning.
- (7) In those patients with AIS inside 6 to 16 hours of last realized typical who have LVO in the front course and meet other Sunrise or Stop 3 qualification standards, MT is suggested.

Various techniques of thrombectomy Old techniques

1. Mechanical clot disruption

This regularly elaborate testing the clots with a miniature guidewire as well as a microcatheter, frequently bringing about a more noteworthy level of progress than normalized treatment alone at that point.

2. Intra-arterial local urokinase infusion

3. Intraluminal clot disruption using ultrasound New techniques

1. Concentric merci retrieval system

The Merci device (Concentric Medical), which was named after the MERCI trial, was the first thrombectomy retrieval device in this class to receive FDA approval. The Concentric Merci Retrieval System, which looks like a corkscrew, is used to remove clots from vessels in persons who have experienced an ischemic stroke (Concentric Medical, Inc, Mountain View, Calif). Until it is ready to be introduced into the clot, the corkscrew is contained in the catheter tip and shielded from the arterial wall. After being embedded in the clot, the device and clot are removed from the vessel.⁽⁴¹⁾

2. Penumbra system

In 2007, the Penumbra aspiration system saw its maiden application. The Penumbra system has a thrombectomy tool that aspirates a thrombus using a reperfusion catheter and breaks up or disrupts clots using a clot separator.⁽⁴¹⁾

3. Clot aspiration thrombectomy

In order to apply negative pressure, a big catheter is attempted to progress to the clot's proximal surface before being manually aspirated with a syringe. When there is no backflow, thrombus entrapment is present. In order to prevent losing the thrombus after it has been trapped, the catheter is gently withdrawn under continual negative pressure. After the introduction of new-generation equ-

ipment, fresh methods for mechanical clot aspiration emerged.⁽⁴²⁾

Forced arterial suction thrombectomy (FAST)

A direct aspiration first pass technique (ADAPT)

4. Stent retriever devices

Stent retrievers are self-expanding stents that can be implanted and recovered. When the device is placed over a thrombus, it forces the thrombus against the vessel wall, typically forming a perfusion channel that immediately begins to restore blood flow. The struts of the stent catch the thrombus in their net. The clot is subsequently grasped by the stent, which is then retrieved. There are two stent retrievers that have FDA approval.⁽⁴¹⁾

-Trepo embolectomy device (Stryker Neurovascular)

-Solitaire FR (Medtronic Neurovascular)

Over 80% of patients signed up for MR CLEAN, Expand IA, Departure, and Quick PRIME went through thrombectomy with a retrievable stent.

5. Combined usage of direct clot aspiration and stent retriever thrombectomy: switching strategy and solumbra technique

Changing from FAST to stent retriever thrombectomy in difficult instances (was defined as three or more failed attempts by the FAST for recanalization). The Solumbra method involves simultaneously using both devices⁽⁴³⁾

However, suction devices can achieve revascularisation rates similar to stent retrievers.⁽⁴⁵⁾ second-generation stent retrievers are preferred for mechanical thrombectomy.⁽⁴⁴⁾




Figure 1: Illustration showing the key developments in thrombectomy technology, from the first-generation concept to cutting-edge techniques. The Development of Thrombectomy Techniques, Ideas, and Equipment for Acute Strokes⁽⁴⁶⁾.

8.Steps of thrombectomy

Mechanical thrombectomy procedures can be performed under conscious sedation or general anaesthesia. Based on each patient's unique risk factors, preferences, and institutional experience, we

should select the anaesthetic procedure.⁽⁴⁴⁾ A femoral arterial puncture is followed by the placement of a large (8Fr) guide catheter, an intermediate catheter (5-6Fr) aiming towards the circle of Willis, and a microcatheter that must be

placed over a micro guidewire to reach the clot. After the device has become one with the clot, it is drawn back into the intermediate catheter, where suction is being applied at the same time. The stent retriever can then glide into the microcatheter and emerge inside the clot, where it opens like a stent, once the microwire is removed (but stays attached to its pusher wire). The intermediate catheter may be avoided when using a balloon guide, which forms a cuff around the guide catheter to reduce forward flow and lower the chance of embolizing the clot's components distally or into other locations. The aspiration of the clot directly into an intermediate catheter is a technique that is gaining popularity because to the development of large lumen catheters that we may safely route into the M1 portion of the middle cerebral artery and beyond. Selecting a catheter with a lumen that is nearly the same size as the conduit in which the clot is trapped can allow the entire clot to be suctioned out; if this is unsuccessful, a stent retriever can simply be put through the original system.

9. complications of endovascular treatment for acute ischemic stroke: Prevention and management

1. Access-site difficulties

It includes injuries to the vessels, nerve damage, and infections. It can cause a retroperitoneal haemorrhage, distal arterial embolization, critical limb ischemia, dissection, and pseudo-aneurysm development. Depending on the circumstances, the management can range from conservative to vascular surgery.⁽⁴⁷⁾

2. Allergic responses

Contrast, latex, or device parts (particularly nickel) might cause allergic react-

ions, however these reactions are rarely severe or life-threatening.

3. a perforated artery

Atherosclerosis and vessel tortuosity are frequent risk factors for this severe consequence. Management: Because it can be partially obstructing the perforation site, the perforating device shouldn't be brought back. Additional options include lowering blood pressure, stopping anticoagulation, and inflating an intracranial balloon. If the bleeding continues, detachable coils or the injection of liquid embolic agents (Onyx) can be utilised to occlude the injured artery segment.⁽⁴⁸⁾

4. Arterial severance

If it is located and detected early, it frequently has no symptoms. However, it can cause significant neurological impairments and raises the likelihood of occlusive or thromboembolic consequences. Any vessel might be affected, and it can happen when manipulating a catheter or guidewire. Management: Anticoagulant or dual antiplatelet medication is advised in cases of non-flow-limiting dissections or asymptomatic patients. While balloon angioplasty or stenting may be required in extreme situations, particularly in flow-limiting dissections.⁽⁴⁹⁾

5. Vasospasm

It happens as a result of catheter manipulation during thrombectomy irritating the blood vessels. Additionally, it could be asymptomatic or more serious, leading to important arterial blockage.

- Management: To reduce irritation if a vasospasm occurs, quickly retract the catheter or guidewire that caused it.

If vasospasm persists, blood pressure may be increased and intra-arterial nimodipine, typically 0.5 mg to 1 mg, may be gradually administered over a number of minutes.⁽⁵⁰⁾ Nimodipine may be used

in catheter flush bags as a preventative measure.

Internal haemorrhage, number six Within 72 hours of MT or during it, serious issues can arise; they may or may not be symptomatic at the time of discovery. Clinical variables have been linked to a higher incidence of symptomatic intracerebral bleeding, including baseline stroke severity, diabetes, a large ischemic core, inadequate cerebral blood flow, and thrombus length >14 mm (sICH). Additionally, it has been discovered that longer thrombectomy procedures are linked to a higher risk of sICH.⁽⁵¹⁾ Reperfusion injury and device-related vascular injury or perforation are additional possible risk factors.⁽⁵²⁾ The origin and extent of the bleeding will determine how it is to be managed.

We could reduce the risk of sICH by carefully choosing patients who would benefit from MT.⁽⁵³⁾

7. Subarachnoid bleeding

Although it is a frequent consequence, severe or extensive SAH can result in neurological decline. In addition to disruption of the cerebral microvascular barriers and intra-procedural artery perforation or dissection, concealed rupture caused by stretching of the arterioles, venules, and subarachnoid spaces during removing the stent-retriever are further mechanisms for SAH. Due to the possibility of delayed hydrocephalus and/or vasospasm, management entails careful observation. If possible, the bleeding must be controlled using the necessary procedures in cases of procedural vascular perforation or dissection.⁽⁵⁴⁾

8. Stent separations

When using stroke thrombectomy equipment from the first generation, it was normal. Stent structural characteristics, the number of stent passes employed during therapy, the kind and length of the

thrombus or plaque, convoluted architecture, arterial wall calcifications, arterial stenosis, and entanglement in the proximal carotid stent are all risk factors for stent detachment. If the target vessel is open, management options include leaving the stent in situ, attempting to recover the detached device with a different device, and finally, surgically extracting the detached stent⁽⁵⁵⁾.

9. Embolization of a newly vascularized area During retrieval, a clot may move distally inside the target artery or proximally to a previously unaffected region (hence, proximal migration may occur). The use of balloon guide catheters reduced the likelihood of it happening. Using a stent retriever, proximal embolization can be removed. For distal embolization, intra-arterial thrombolytics may be employed⁽⁵⁶⁾.

10. Causes & solutions of endovascular treatment failure

1-Couple impediments of cervical vein and intracranial corridor

2-Gigantic clumps in the ICA notwithstanding intracranial impediment

On account of countless clusters in the cervical vein corresponding with a couple intracranial course impediment, it is preposterous to expect to eliminate each of the coagulations utilizing only a stent retriever (SR). In that particular situation, it is more viable first to play out a pull thrombectomy utilizing an inflatable directed catheter (BGC) or potentially enormous drag transport sheath before the SR thrombectomy. Following the pull thrombectomy, a SR thrombectomy can be performed to eliminate any leftover distal clumps.⁽⁵⁷⁾

3-Extreme blood vessel convolution

The gamble of losing the SR-connected with clusters increments in the event that the important parent course is exceptionally convoluted or has a stenotic portion near the impediment site. Furthermore, it's conceivable that BGC pull alone won't be sufficient to stop distal embolization. The probability of complete cluster extraction in this present circumstance might be expanded by utilizing a coaxial 5 F (viable with a 8 F BGC) or 6 F middle (viable with a 9 F BGC).⁽⁵⁷⁾

4-Unmanageable impediment to mechanical thrombectomy

The pathomechanism of an intense huge vein impediment (embolic versus non embolic) or the actual properties of the coagulation (delicate versus hard/coordinated) can assume a critical part in the reaction to a SR.⁽⁵⁷⁾

The larger parts of non-embolic impediments are truncal type impediments, and most are because of intracranial atherosclerotic stenosis. It will in general show obstinacy to a SR because of rehashed re-impediment. Likewise, the utilization of a SR can bring about additional platelet enactment, prompting rehashed re-impediment.

To forestall re-impediment, the primary choice is to oversee a glycol-protein IIb/IIIa inhibitor, which inactivates platelets and consequently forestalls rehashed re-impediment. Furthermore, in hard-headed cases, super durable stenting regardless of inflatable angioplasty can be applied.⁽⁵⁷⁾

For effective recanalization of a LVO because of a coordinated coagulation, the first and easiest choice is the intra-blood vessel organization of a

vasodilator and expanding the vessel breadth to ease cluster recovery.

The subsequent choice is the concurrent usage of a SR and desire or halfway catheter. On the off chance that the coordinated coagulation is as yet headstrong after the concurrent use of a SR and a halfway catheter, extremely durable stenting can be considered as a last reestablish.⁽⁵⁷⁾

11.Conclusion

Recent years have seen a significant advancement in the management of acute ischemic stroke, and mechanical thrombectomy is now thought to be standard of care in some patients with major artery blockage in the anterior circulation.

References

1. Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. *Circulation*. (2017) 135:759–71. doi: 10.1161/CIRCULATIONAHA.116.025250.
2. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke_ a meta-analysis of individual patient data from five randomised trials. *Lancet*. (2016) 387:1723–31. doi: 10.1016/S0140-6736(16)00163-X.
3. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med*. (2018) 378:708–18. doi: 10.1056/NEJMoa1713973.
4. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and

- infarct. *N Engl J Med.* (2018) 378:11–21. doi: 10.1056/NEJMoa1706442.
5. Jovin TG, Desai SM, Aghaebrahim A, Ducruet AF, Giurgiutiu DV, Gross BA, et al. Neurothrombectomy for acute ischemic stroke across clinical trial design and technique: a single center pooled analysis. *Front Neurol.* (2020) 11:1047. doi: 10.3389/fneur.2020.01047.
 6. Papanagiotou P, Roth C, Walter S, Behnke S, Politi M, Fassbender K, Haass A, Reith W: Treatment of acute cerebral artery occlusion with a fully recoverable intracranial stent. *Circulation* 2010, 121(23):2605-2606.
 7. Pérez MA, Miloslavski E, Fischer S, Bänzner H, Henkes H: Intracranial thrombectomy using the Solitaire stent: a historical vignette. *Journal of neurointerventional surgery* 2012, 4(6):e32-e32.
 8. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *The lancet* 2012, 380(9859):2095-2128.
 9. Feigin VL, Norrving B, Mensah GA: Global burden of stroke. *Circulation research* 2017, 120(3):439-448.
 10. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The lancet* 2012, 380(9859):2197-2223.
 11. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson LM, Truelsen T: Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. *The Lancet Global Health* 2013, 1(5):e259-e281.
 12. Strong K, Mathers C, Bonita R: Preventing stroke: saving lives around the world. *The Lancet Neurology* 2007, 6(2):182-187.
 13. Abd-Allah F, Moustafa RR: Burden of stroke in Egypt: current status and opportunities. *International Journal of Stroke* 2014, 9(8):1105-1108.
 14. Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, Fisher M, Pandian J, Lindsay P: World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. *International Journal of Stroke* 2022, 17(1):18-29.
 15. Khedr EM, Elfetoh NA, Al Attar G, Ahmed MA, Ali AM, Hamdy A, Kandil MR, Farweez H: Epidemiological study and risk factors of stroke in Assiut Governorate, Egypt: communitybased study. *Neuroepidemiology* 2013, 40(4):288-294.
 16. Mishra LD: Cerebral blood flow and anaesthesia: a review. *Indian J Anaesth* 2002, 46(2):87-95.
 17. Luo Z, Ding X: Ischemic cerebral vascular disease. Beijing: People's Medical Publishing House 2012.
 18. Mui K, Yoo A, Verduzco L, Copen W, Hirsch J, González R, Schaefer P: Cerebral blood flow thresholds for tissue infarction in patients with acute ischemic stroke treated with intra-arterial revascularization therapy depend on timing of reperfusion. *American Journal of Neuroradiology* 2011, 32(5):846-851.
 19. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM: Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. *Jama* 1999, 282(21):2003-2011.
 20. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. *Stroke* 2005, 36(7):1432-1438.
 21. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL,

- Rymer MM, Higashida RT, Starkman S: Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke* 2008, 39(4):1205-1212.
22. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. *New England Journal of Medicine* 2013, 368(10):893-903.
23. Broderick JP, Schroth G: What the SWIFT and TREVO II trials tell us about the role of endovascular therapy for acute stroke. *Stroke* 2013, 44(6):1761-1764.
24. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH: A trial of imaging selection and endovascular treatment for ischemic stroke. *New England Journal of Medicine* 2013, 368(10):914-923.
25. Demchuk AM, Goyal M, Yeatts SD, Carrozzella J, Foster LD, Qazi E, Hill MD, Jovin TG, Ribo M, Yan B: Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. *Radiology* 2014, 273(1):202-210.
26. Berkhemer OA, Fransen PS, Beumer D, Van Den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJ: A randomized trial of intraarterial treatment for acute ischemic stroke. *New England Journal of Medicine* 2015, 372(1):11-20.
27. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, San Román L, Serena J, Abilleira S, Ribó M: Thrombectomy within 8 hours after symptom onset in ischemic stroke. *New England Journal of Medicine* 2015, 372(24):2296-2306.
28. Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W: Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *New England Journal of Medicine* 2015, 372(24):2285-2295.
29. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ: Endovascular therapy for ischemic stroke with perfusion-imaging selection. *New England Journal of Medicine* 2015, 372(11):1009-1018.
30. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL: Randomized assessment of rapid endovascular treatment of ischemic stroke. *New England Journal of Medicine* 2015, 372(11):1019-1030.
31. Goyal M, Menon BK, van Zwam WH, Dippel D, Mitchell P, Demchuk A, Dávalos A, Majoie C, van der Lugt A, De Miquel M: HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* 2016, 387(10029):1723-1731.
32. Joshi KC, Chen M: Indications for Mechanical Thrombectomy. In: *Acute Stroke Management in the Era of Thrombectomy*. Springer; 2019: 25-37.
33. Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, Amarenco P, Carrozzella J, Spilker J, Foster LD: Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. *The Lancet Neurology* 2014, 13(6):567-574.
34. Macleod M, Davis S, Mitchell PJ, Gerraty R, Fitt G, Hankey GJ, Stewart-Wynne E, Rosen D, McNeil JJ, Bladin C: Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. *Cerebrovascular diseases* 2005, 20(1):12-17.
35. Langezaal LC, van der Hoeven E, Mont'A verne F de Carva o Li a FO, Dippe D van der Lugt A, Lo RT, Boiten J, Lycklama à Nijeholt GJ: Endovascular

- therapy for stroke due to basilar artery occlusion. *New England Journal of Medicine* 2021, 384(20):1910-1920.
36. Rangel-Castilla L, Rajah GB, Shakir HJ, Shallwani H, Gandhi S, Davies JM, Snyder KV, Levy EI, Siddiqui AH: Management of acute ischemic stroke due to tandem occlusion: should endovascular recanalization of the extracranial or intracranial occlusive lesion be done first? *Neurosurgical focus* 2017, 42(4):E16.
37. Investigators TR: The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. *Circulation* 1997, 96(5):1445-1453.
38. Papanagiotou P, Ntaios G: Endovascular thrombectomy in acute ischemic stroke. *Circulation: Cardiovascular Interventions* 2018, 11(1):e005362.
39. Papanagiotou P, Reith W, Kastrup A, Roth C: Current reperfusion strategies for acute stroke. *Interventional cardiology clinics* 2014, 3(1):145-167.
40. Campbell BC, Donnan GA, Mitchell PJ, Davis SM: Endovascular thrombectomy for stroke: current best practice and future goals. *Stroke and vascular neurology* 2016, 1(1):16-22.
41. Spiotta AM, Chaudry MI, Hui FK, Turner RD, Kellogg RT, Turk AS: Evolution of thrombectomy approaches and devices for acute stroke: a technical review. *Journal of neurointerventional surgery* 2015, 7(1):2-7.
42. Turk AS, Frei D, Fiorella D, Mocco J, Baxter B, Siddiqui A, Spiotta A, Mokin M, Dewan M, Quarfordt S: ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy. *Journal of neurointerventional surgery* 2018, 10(Suppl 1):i4-i7.
43. Humphries W, Hoit D, Doss VT, Elijovich L, Frei D, Loy D, Dooley G, Turk AS, Chaudry I, Turner R: Distal aspiration with retrievable stent assisted thrombectomy for the treatment of acute ischemic stroke. *Journal of neurointerventional surgery* 2015, 7(2):90-94.
44. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B: 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2018, 49(3):e46-e99.
45. Lapergue B, Blanc R, Gory B, Labreuche J, Duhamel A, Marnat G, Saleme S, Costalat V, Bracard S, Desal H: Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: the ASTER randomized clinical trial. *Jama* 2017, 318(5):443-452.
46. Spiotta AM, Hui FK: Evolution of Thrombectomy Approaches, Philosophy, and Devices for Acute Stroke. In: *Management of Cerebrovascular Disorders*. Springer; 2019: 487-510.
47. Shah VA, Martin CO, Hawkins AM, Holloway WE, Junna S, Akhtar N: Groin complications in endovascular mechanical thrombectomy for acute ischemic stroke: a 10-year single center experience. *Journal of neurointerventional surgery* 2016, 8(6):568-570.
48. Mokin M, Fargen KM, Primiani CT, Ren Z, Dumont TM, Brasiliense LB, Dabus G, Linfante I, Kan P, Srinivasan VM: Vessel perforation during stent retriever thrombectomy for acute ischemic stroke: technical details and clinical outcomes. *Journal of neurointerventional surgery* 2017, 9(10):922-928.
49. Davis MC, Deveikis JP, Harrigan MR: Clinical presentation, imaging, and management of complications due to neurointerventional procedures. In: *Seminars in interventional radiology*: 2015: Thieme Medical Publishers; 2015: 098-107.
50. Akpınar SH, Yılmaz G: Periprocedural complications in endovascular stroke

- treatment. The British journal of radiology 2016, 89(1057):20150267.
51. Soize S, Barbe C, Kadziolka K, Estrade L, Serre I, Pierot L: Predictive factors of outcome and hemorrhage after acute ischemic stroke treated by mechanical thrombectomy with a stent retriever. *Neuroradiology* 2013, 55(8):977-987.
52. Nogueira RG, Gupta R, Jovin TG, Levy EI, Liebeskind DS, Zaidat OO, Rai A, Hirsch JA, Hsu DP, Rymer MM: Predictors and clinical relevance of hemorrhagic transformation after endovascular therapy for anterior circulation large vessel occlusion strokes: a multicenter retrospective analysis of 1122 patients. *Journal of neurointerventional surgery* 2015, 7(1):16-21.
53. Balami JS, White PM, McMeekin PJ, Ford GA, Buchan AM: Complications of endovascular treatment for acute ischemic stroke: prevention and management. *International Journal of Stroke* 2018, 13(4):348-361.
54. Yub Lee S, Won Youn S, Kyun Kim H, Rok Do Y: Inadvertent detachment of a retrievable intracranial stent: review of manufacturer and user facility device experience. *The neuroradiology journal* 2015, 28(2):172-176.
55. Chueh J-Y, Puri AS, Wakhloo AK, Gounis MJ: Risk of distal embolization with stent retriever thrombectomy and ADAPT. *Journal of neurointerventional surgery* 2016, 8(2):197-202.
56. Darkhabani Z, Nguyen T, Lazzaro MA, Zaidat OO, Lynch JR, Fitzsimmons B-F, Linfante I: Complications of endovascular therapy for acute ischemic stroke and proposed management approach. *Neurology* 2012, 79(13 Supplement 1):S192-S198.
57. Kim BM: Refractory occlusion to stentriever thrombectomy: etiological considerations and suggested solutions. In: *Acute Ischemic Stroke*. Springer; 2017: 213-226.